Patent 12083103
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Active provider: Google · gemini-2.5-flash
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Veloxis Pharmaceuticals AS
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Proceedings overview
There are no AIA trial proceedings on file for US Patent 12,083,103 as of June 1, 2026. This indicates that the patent has not yet been challenged through Inter Partes Review (IPR), Post-Grant Review (PGR), or Covered Business Method (CBM) review before the Patent Trial and Appeal Board (PTAB).
Strategic summary
Currently, all claims of US Patent 12,083,103 remain untested in AIA trial proceedings. This means there is no estoppel landscape established by the PTAB for this patent, and all prior-art grounds remain available for potential challengers. The absence of PTAB activity suggests that the patent has not yet faced direct validity challenges in this forum.
Recommended next steps
As there is no PTAB activity on file for US Patent 12,083,103, potential defendants considering challenging the patent's validity could initiate an AIA trial proceeding, such as an Inter Partes Review, if the statutory requirements and timelines are met. Given the patent's issue date of September 10, 2024, the nine-month window for filing a Post-Grant Review (PGR) has likely closed (around June 10, 2025). However, the window for filing an Inter Partes Review (IPR) remains open, provided the challenger is not time-barred by being served with a complaint alleging infringement more than one year prior. The absence of PTAB activity is a notable signal, as well-asserted patents often attract IPRs.
Generated 6/1/2026, 12:47:45 AM